AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04273308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration training
Description: The experimental group participated in a 12-week whole-body vibration training that was conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time. The control group were provided home DVDs on resistance exercise and manuals for preventing frailty
Study NCT04252651 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: This study will involve blood draws to test for specific cytokines
Study NCT03345771 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial Barrier Dressing
Description: Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.
Study NCT03345771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy (NPWT)
Description: PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
Study NCT01075672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
Study NCT00455572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK1572932A
Description: Intramuscular injection, 8 doses
Study NCT00455572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Description: Four cycles with doses based on patient's body surface area, intravenous administration
Study NCT00455572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Four cycles with doses based on patient's body surface area , intravenous administration
Study NCT00455572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Regimen will be based upon the site's own standard procedures
Study NCT02917421 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: (Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
Study NCT03833908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAF-1217
Description: Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
Study NCT00006401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNO
Description: Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
Study NCT00006401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Nitrogen
Study NCT02037009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care organization (anesthetic surveillance)
Study NCT02408978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXP005
Study NCT02408978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Study NCT05125614 — intervention group
Intervention type: OTHER
Intervention: No adjuvant chemotherapy
Description: There is no intervention differences between 2 groups. We analyzed the data of the patients who did not receive adjuvant chemotherapy.
Study NCT02872584 — intervention group
Intervention type: DRUG
Intervention: Prednisone
Description: prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
Study NCT02368860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, irinotecan, capecitabine
Description: fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
Study NCT06260462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dual-release hydrocortisone
Description: Oral tablets 20-25-30-40 mg/day
Study NCT06260462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional glucocortidois
Description: Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
Study NCT03778021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Gardening Exposure
Description: Assistance provided with planting and maintaining the school garden
Study NCT03778021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Gardening Curriculum
Description: 14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
Study NCT02980666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 0.05 mg/kg/day SC injection once daily for 24 weeks.
Study NCT01829321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0974
Description: 1 capsule in the morning and 1 capsule in the evening with food during 28 days
Study NCT01829321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule in the morning and 1 capsule in the evening with food during 28 days
Study NCT03331302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon-129 MRI (Experimental)
Description: MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
Study NCT00783614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral therapy (ART)
Description: Patients randomized to start ART immediately or defer use for 1 month
Study NCT00783614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiretroviral therapy (ART)
Description: Patients randomized to start ART immediately or defer use for 1 month
Study NCT02497729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Written Checklist
Description: Use of a written checklist pre and peri-intubation
Study NCT02497729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head of Bed Up
Description: Raising the patient's head of bed to 25 degrees
Study NCT06392334 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy
Description: Biopsy of lung tissue
Study NCT04430504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary telerehabilitation
Description: weekly video meetings to instruct and monitor self-exercises at home
Study NCT01671033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
Study NCT01671033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation
Description: Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
Study NCT03331302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioactive Xenon-133 scintigraphy (Active Comparator)
Description: Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
Study NCT00902759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Program
Description: Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program.
Study NCT04456621 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PBT
Description: Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
Study NCT01588899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU uterine fibroid treatment
Description: A single treatment session for uterine fibroids with the MR-HIFU device.
Study NCT00627250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Amantadine 100 mg every morning and 12 noon
Study NCT00627250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amantadine
Description: Amantadine 100 mg every morning and 12 noon
Study NCT01359904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Dialysate bath
Description: The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
Study NCT02557191 — intervention group
Intervention type: OTHER
Intervention: Observational study
Study NCT04357756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
Study NCT04357756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
Study NCT00990782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PillCam ESO Capsule Endoscope
Description: Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
Study NCT01587716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345 (Inhaled) Single Dose
Description: 250, 1000 and 2000 microgram (proposed doses)
Study NCT01587716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Inhaled) Single Dose
Description: Inhaled 0.9% sodium chloride solution
Study NCT01587716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2339345 (Inhaled) Repeat Dose
Description: 2000 microgram (proposed dose) administered 4 times a day for two consecutive days
Study NCT01587716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Inhaled) Repeat Dose
Description: Inhaled 0.9% sodium cholride solution
Study NCT00267826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
Study NCT02340117 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-53
Description: The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
Study NCT02340117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
Study NCT02340117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
Study NCT01400191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
Study NCT03217916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Elisa assay of podocyte glycoprotein in urine
Description: Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information.
Study NCT04004975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
Study NCT00135811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin
Description: Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
Study NCT00135811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF and Dexamethasone
Description: MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg
Study NCT03472391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
Study NCT00720668 — intervention group
Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: radiofrequency ablation for HCC
Study NCT01156974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education and care guide
Description: Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
Study NCT01156974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education only
Description: patients receive education about care goals
Study NCT04309149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT fats
Description: Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
Study NCT01195662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, once daily, Up to 12 weeks
Study NCT01195662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Dapagliflozin
Description: Tablets, Oral, 0 mg, once daily, Up to 12 weeks
Study NCT04156113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yo-Yo intermittent recovery test (level 1)
Description: The Yo-Yo intermittent recovery test (level 1) will be administered once.
Study NCT01878968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Script and CPR/Mechanical ventilation video.
Description: Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
Study NCT04249908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifovir Dipivoxil Maleate
Description: Besifovir 150 mg q.d.
Study NCT04249908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir Dipivoxil Maleate
Description: Besifovir 150 mg q.d.
Study NCT01518894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.10 mg oral solution Q24 hours for 14 days
Study NCT01518894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.20 mg oral solution Q24 hours for 14 days
Study NCT01518894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
Study NCT01518894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution Q24 hours for 14 days
Study NCT00118209 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: IV
Study NCT00118209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: IV
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV
Study NCT02166619 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS + physical therapy
Description: Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy
Study NCT02166619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + physical therapy
Description: Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy
Study NCT04331470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole Pill + Budesonide+Formoterol inhaler
Description: Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
Study NCT04331470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir + hydoxychloroquine
Description: Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
Study NCT04331470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir + hydoxychloroquine
Description: Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
Study NCT02664506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word repetition after a time delay.
Description: This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
Study NCT03494296 — intervention group
Intervention type: DRUG
Intervention: patients received D-COP regimen chemotherapy
Description: patients received D-COP regimen chemotherapy
Study NCT01396213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide Acetate
Description: gelatin capsule